A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy

Current Cancer Drug Targets

Volumn 10, Issue 3, 2010, Pages 343-353

  Paliwal, S R ^a   Paliwal, R ^a   Mishra, N ^a   Mehta, A ^a   Vyas, S P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Breast cancer; Doxorubicin; Estrone; Stealth liposomes; Targeting

Indexed keywords

6 CARBOXYFLUORESCEIN; DOXORUBICIN; ESTROGEN RECEPTOR; ESTRONE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN TARGETING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG COMPOUNDING; ESTRONE; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RECEPTORS, ESTROGEN; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952858546     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791190210     Document Type: Article

References (48)

1. Eliaz, R. E.; Nir, S.; Marty, C.; Szoka, F. Determination and modelling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004, 64, 711-718.
2. Drummond, D.; Meyer, O.; Hong, K.; Kirpotin, D.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51, 691-743.
3. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
4. Lu, W. L.; Qi, X. R.; Zhang, Q.; Li, R. Y.; Wang, G. L.; Zhang, R. J.; Wei, S. L. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J. Pharmacol. Sci. 2004, 95, 381-389.
5. Papahadjopoulos, D.; Allen, T. M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S. K.; Lee, K. D.; Woodle, M. C.; Lasic, D. D.; Redemann, C.; Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 1991, 88, 11460-11464.
6. Rusch, V.; Mendelsohn, J.; Dmitrovsky, E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 1996, 7, 133-141.
7. Weitman, S. D.; Lark, R. H.; Coney, L. R.; Fort, D. W.; Frasca, V.; Zurawski, V. R.; Kamen, B. A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992, 52, 3396-3401.
8. Recht, L.; Torres, C. O.; Smith, T. W.; Raso, V.; Griffin, T. W. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg. 1990, 72, 941-945.
9. Seymour, L. W. Soluble polymer for lectin-mediated targeting. Adv. Drug Del. Rev. 1994, 14, 89-111.
10. Harding, M.; Cowan, S.; Hole, D.; Cassidy, L.; Kitchener, H.; Davis, J.; Leake, R. Estrogen and progesterone receptors in ovarian cancer. Cancer 1990, 65, 486-491.
11. Loven, D.; Rakowsky, E.; Geier, A.; Lunenfeld, B.; Rubinstein, A.; Klein, B.; Lurie, H. A clinical evaluation of nuclear estrogen receptors combined with cytosolic estrogen and progesterone receptors in breast cancer. Cancer 1990, 66, 341-346.
12. Henderson, B. E.; Ross, R.; Bernstein, L. Estrogens as a Cause of Human Cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1988, 48, 246-253.
13. Marquez, D. C.; Pietra, R. J. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20, 5420-5430.
14. Osborne, C. K. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998, 51, 227-238.
15. Holmes, F. A.; Walters, R. S.; Theriault, R. L.; Forman, A. D.; Newton, L. K.; Raber, M. N.; Buzdar, A. U.; Frye, D. K.; Hortobagyi, G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 1991, 83, 1797-1805.
16. Boyle, R. W.; Johnson, C. K.; Dolphin, D. J. A convenient entry to asymmetrically meso-substituted porphyrins. Chem. Commun. 1995, 5, 527-528.
17. Reddy, B. S.; Banerjee, R. 17 -estradiol-associated stealthliposomal delivery of anticancer gene to breast cancer cells. Angew Chem. Int. Ed. 2005, 44, 6723-6727.
18. Rai, S.; Paliwal, R.; Vaidya, B.; Khatri, K.; Goyal, A. K.; Gupta, P. N.; Vyas, S. P. Targeted delivery of doxorubicin via estroneappended liposomes. J. Drug Target 2008, 16, 455-463.
19. Zalipsky, S.; Gilon, C.; Zalkha, A. Attachment of drugs to polyethylene glycols. Eur. Polym. J. 1983, 19, 1177-1183.
20. Haran, G.; Cohen, R.; Bar, L. K.; Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable. Entrapment of amphipathic weak base. Biochem. Biophys. Acta 1993, 115, 201-215.
21. Manosroi, A.; Kongkaneramit, L. L.; Manosroi, J. Characterization of amphotericin B liposome formulation. Drug Dev. Ind. Pharm. 2004, 30, 535-543.
22. Fry, D. W.; White, J. C.; Goldman, I. D. Rapid separation of low molecular weight solutes from liposomes without dilution. J. Anal. Biochem. 1978, 90, 809-815.
23. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol. Methods 1983, 65, 55-63.
24. Rose, L. M.; Tillery, K. F.; Dareer, S. M.; Hill, D. L. Highperformance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue. J. Chromatogr. 1988, 425, 419-423.
25. Foster, P. A.; Newman, S. P.; Chander, S. K.; Stengel, C.; Jhalli, R.; Woo, L. L.; Potter, B. V.; Reed, M. J.; Purohit, A. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin. Cancer Res. 2006, 12, 5543-5549.
26. Lagiou, P.; Georgila, C.; Samoli, E.; Lagiou, A.; Zourna, P.; Minaki, P.; Vassilarou, D.; Papadiamandis, I.; Sfikas, C.; Kalapothaki, V.; Sekeris, C. E.; Trichopoulos, D. Estrogen alpha and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk. Int. J. Cancer 2009, 124, 440-442.
27. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
28. Murdoch, F. E.; Gorski, J. The role of ligand in estrogen receptor regulation of gene expression. Mol. Cell Endocrinol. 1991, 78, C103-C108.
29. Szego, C. M.; Davis, J. S. Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. Proc. Natl. Acad. Sci. USA 1967, 58, 1711-1718.
30. Aronica, S.; Katzenellenbogen, B. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 1993, 7, 743-752.
31. Aronica, S.; Kraus, W.; Katzenellenbogen, B. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. USA 1994, 91, 8517-8521.
32. Levin, E. R. Cellular Functions of the Plasma Membrane Estrogen Receptor. Trends Endocrinol. Metab. 1999, 10, 374-377.
33. Pietras, R. J.; Szego, C. M. Influence of antidiuretic hormone on release of lysosomal hydrolase at mucosal surface of epithelial cells from urinary bladder. Nature 1975, 253, 357-359.
34. Mendelsohn, M. E.; Karas, R. H. The protective effects of estrogen on the cardiovascular system. New Engl. J. Med. 1999, 340, 1801-1811.
35. Migliaccio, A.; Di Domenico, M.; Castoria, G.; de Falco, A.; Bontempo, P.; Nola, E.; Auricchio, F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15, 1292-1300.
36. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57, 727-741.
37. Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268, 235-237.
38. Allen, T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 1994, 15, 215-220.
39. Bolotin, E. M.; Cohen, R.; Bar, L. K.; Emanuel, S. N.; Lasic, D. D.; Barenholz, Y. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposome Res. 1994, 4, 455-479.
40. Karajgi, J.; Jain, N. K.; Vyas, S. P. Passive vectoring of a colloidal carrier system for sodium stibogluconate: preparation, characterization and performance evaluation. J. Drug Target 1993, 1, 197-206.
41. Lasic, D. D.; Frederik, P. M.; Stuart, M. C. Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett. 1992, 312, 255-258.
42. Charrois, G. J. R.; Allen, T. M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004, 1663, 167-177.
43. Junping, W.; Maitani, Y.; Takayama, K.; Nagai, T. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Int. J. Pharm. 2000, 203, 61-69.
44. Speth, P. A. J.; Hoesel, Q. G.; Haanen, C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinetic 1988, 15, 15-31.
45. Schmid, P.; Possinger, K. Liposomal anthracyclines for improved cardiac tolerability. The Breast 2001, 2, 2-27.
46. Hanstein, B.; Liu, H.; Yancisin, M.; Brown, M. Functional analysis of a novel estrogen receptor-beta isoform. Mol. Endocrinol. 1999, 13, 129-137.
47. Rai, S.; Paliwal, R.; Vaidya, B.; Gupta, P. N.; Mahor, S.; Khatri, K.; Goyal, A. K.; Rawat, A.; Vyas, S. P. Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA Delivery. Curr. Med. Chem. 2007, 14, 2095-2109.
48. Keely, N. O.; Meegan, M. J. Targeting tumors using estrogen receptor ligand conjugates. Curr. Cancer Drug Targets 2009, 9, 370-380.